TELA Stock Forecast 2025-2026
Distance to TELA Price Targets
TELA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Tela Bio (TELA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TELA and similar high-potential opportunities.
Latest TELA Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, TELA has a bullish consensus with a median price target of $10.50 (ranging from $5.00 to $12.00). Currently trading at $2.35, the median forecast implies a 346.8% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Caitlin Cronin at Canaccord Genuity, projecting a 410.6% upside. Conversely, the most conservative target is provided by Matt O'Brien at Piper Sandler, suggesting a 112.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TELA Analyst Ratings
TELA Price Target Range
Latest TELA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TELA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 8, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $5.00 |
| Oct 4, 2024 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $12.00 |
| Aug 13, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $8.00 |
| Aug 13, 2024 | JMP Securities | David Turkaly | Market Outperform | Maintains | $12.00 |
| Aug 13, 2024 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $12.00 |
| Aug 13, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $8.00 |
| Jul 25, 2024 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $14.00 |
| May 10, 2024 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $10.00 |
| Mar 22, 2024 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $15.00 |
| Mar 22, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $12.00 |
| Dec 27, 2023 | Lake Street | Frank Takkinen | Buy | Reiterates | $14.00 |
| Nov 10, 2023 | JMP Securities | David Turkaly | Market Outperform | Maintains | $15.00 |
| Mar 28, 2023 | Canaccord Genuity | Kyle Rose | Buy | Reiterates | $15.00 |
| Mar 22, 2023 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $20.00 |
| Nov 10, 2022 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $15.00 |
| Nov 10, 2022 | JMP Securities | David Turkaly | Market Outperform | Maintains | $20.00 |
| Aug 13, 2020 | Piper Sandler | Overweight | Maintains | $17.00 | |
| Jul 9, 2020 | Jefferies | Buy | Maintains | $20.00 | |
| Jun 18, 2020 | JMP Securities | Market Outperform | Maintains | $24.00 | |
| Jun 10, 2020 | Canaccord Genuity | Buy | Maintains | $20.00 |
Tela Bio Inc. (TELA) Competitors
The following stocks are similar to Tela Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tela Bio Inc. (TELA) Financial Data
Tela Bio Inc. has a market capitalization of $92.56M with a P/E ratio of -1.2x. The company generates $68.65M in trailing twelve-month revenue with a -60.5% profit margin.
Revenue growth is +25.9% quarter-over-quarter, while maintaining an operating margin of -49.4% and return on equity of -342.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Tela Bio Inc. (TELA) Business Model
About Tela Bio Inc.
Develops innovative soft tissue reconstruction solutions.
Tela Bio Inc. generates revenue by developing and commercializing advanced medical products for soft tissue repair, particularly in general surgery and hernia repair. Its proprietary product lines, OviTex and OviTex PRS, utilize a combination of biologic and synthetic materials to enhance surgical outcomes and reduce complications.
The company operates at the intersection of biotechnology and medical devices, aiming to improve patient care by providing more effective solutions for surgeons and patients. With its innovative approach, Tela Bio is pivotal in advancing soft tissue reconstruction technologies in the medical field.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
227
CEO
Mr. Antony Koblish
Country
United States
IPO Year
2019
Website
www.telabio.comTela Bio Inc. (TELA) Latest News & Analysis
TELA Bio, Inc. (NASDAQ: TELA) will report its Q4 and full year 2024 financial results on March 20, 2025, followed by a conference call at 4:30 p.m. ET for discussion and updates.
TELA Bio's upcoming financial results announcement could impact stock performance, providing insights into its growth and operational health, influencing investor sentiment and decisions.
TELA Bio, Inc. granted 4,000 restricted stock units to seven new employees as part of their compensation, effective January 21, 2025, under Nasdaq's inducement grant exception.
The issuance of restricted stock units to new employees signals TELA Bio's growth and recruitment strategy, potentially enhancing talent and innovation, which can positively impact future performance and stock value.
TELA Bio, Inc. (NASDAQ: TELA) will participate in Piper Sandler's 36th Annual Healthcare Conference, focusing on soft-tissue reconstruction solutions.
Participation in a prominent healthcare conference can enhance TELA Bio's visibility, attract potential investors, and signal growth opportunities, impacting stock performance and market interest.
TELA Bio, Inc. (NASDAQ: TELA) will hold its Q3 2024 earnings conference call on November 7, 2024, at 4:30 PM ET, featuring key executives and analysts.
The TELA Bio Q3 2024 earnings call offers insights into financial performance and future strategies, influencing stock valuation and investor sentiment.
TELA Bio, Inc. reported a quarterly loss of $0.42 per share, worse than the expected loss of $0.37, but an improvement from a loss of $0.45 per share a year earlier.
TELA Bio's larger-than-expected quarterly loss may signal ongoing financial struggles, impacting investor sentiment and stock performance. Year-over-year improvement could provide some reassurance.
TELA Bio, Inc. closed a public offering of 14.67 million shares at $2.25 each, raising $46 million. This includes pre-funded warrants for 5.8 million shares at $2.2499 each.
TELA Bio raised $46 million through a public offering, enhancing liquidity for growth initiatives. This can positively impact stock performance and investor confidence.
Frequently Asked Questions About TELA Stock
What is Tela Bio Inc.'s (TELA) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Tela Bio Inc. (TELA) has a median price target of $10.50. The highest price target is $12.00 and the lowest is $5.00.
Is TELA stock a good investment in 2025?
According to current analyst ratings, TELA has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TELA stock?
Wall Street analysts predict TELA stock could reach $10.50 in the next 12 months. This represents a 346.8% increase from the current price of $2.35. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tela Bio Inc.'s business model?
Tela Bio Inc. generates revenue by developing and commercializing advanced medical products for soft tissue repair, particularly in general surgery and hernia repair. Its proprietary product lines, OviTex and OviTex PRS, utilize a combination of biologic and synthetic materials to enhance surgical outcomes and reduce complications.
What is the highest forecasted price for TELA Tela Bio Inc.?
The highest price target for TELA is $12.00 from Caitlin Cronin at Canaccord Genuity, which represents a 410.6% increase from the current price of $2.35.
What is the lowest forecasted price for TELA Tela Bio Inc.?
The lowest price target for TELA is $5.00 from Matt O'Brien at Piper Sandler, which represents a 112.8% increase from the current price of $2.35.
What is the overall TELA consensus from analysts for Tela Bio Inc.?
The overall analyst consensus for TELA is bullish. Out of 6 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.50.
How accurate are TELA stock price projections?
Stock price projections, including those for Tela Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
